AstraZeneca PLC (NYSE: AZN) recently expanded its oncology footprint on the New York Stock Exchange with a new regulatory victory. The U.S. Food and Drug…
February 20, 2026
February 12, 2026
Novo Capitalizes on Shift from Injections to Oral Therapies
Novo Nordisk (NYSE: NVO) remains the dominant force in the rapidly expanding metabolic health market, continuing to experience unprecedented demand for its semaglutide products. Recent…
February 11, 2026
The “Amazon Effect”: $4 Trillion Threat to Healthcare Sector
Amazon.com Inc. (NASDAQ: AMZN) is aggressively scaling its pharmaceutical logistics to capture a larger share of the domestic healthcare market. The company recently announced a…
February 10, 2026
AbbVie Invests $100M to Future-Proof Domestic Drug Production
AbbVie (NYSE: ABBV) is prioritizing its domestic production capabilities through a series of multi-million dollar capital investments. The New York Stock Exchange-listed firm aims to…
January 22, 2026
60 Degrees Pharmaceuticals Partners with Runway Health to Expand Access to Malaria Prevention
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has teamed up with Runway Health to make malaria prevention more accessible for international travelers. Starting April 2, 2026, this…
November 18, 2025
Arrowhead Pharmaceuticals Secures FDA Approval for REDEMPLO® (Plozasiran) to Treat Familial Chylomicronemia Syndrome (FCS)
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced a groundbreaking milestone with the U.S. Food and Drug Administration (FDA) granting approval for REDEMPLO® (plozasiran), a small…
Merck (NYSE: MRK) has announced plans to acquire Cidara Therapeutics (NASDAQ: CDTX) in a cash deal valued at $221.50 per share, bringing the total transaction…
The Trump administration is set to announce a groundbreaking deal with pharmaceutical giants Eli Lilly (NYSE: LLY)and Novo Nordisk (NYSE: NVO), making popular obesity drugs…
AbbVie (NYSE: ABBV) has announced encouraging news for people living with vitiligo. The pharmaceutical company shared positive results from two large-scale clinical trials for its…
Eli Lilly (NYSE:LLY) is gearing up for a major launch, having already produced billions of doses of its next-generation weight-loss pill in anticipation of strong…
October 22, 2025
Plus Therapeutics Advances CNSide Diagnostic Commercialization
Plus Therapeutics (NASDAQ: PSTV) has announced significant progress in the commercialization of its CNSide Diagnostic platform, focusing on expanding manufacturing capacity, enhancing commercial readiness, and…
October 21, 2025
Plus Therapeutics Advances CNSide® Diagnostic Platform Launch
Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company specializing in targeted radiotherapeutics for central nervous system (CNS) cancers, has announced significant progress in the…